sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
Mitchell E FaneBrett L EckerAmanpreet KaurGloria E MarinoGretchen M AliceaStephen M DouglassYash ChhabraMarie R WebsterAndrea MarshallRichard CollingOlivia EspinosaNicholas CoupeNeera MarooLeticia CampoMark Ross MiddletonPhilippa CorrieXiaowei XuGiorgos C KarakousisAshani T WeeraratnaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
VEGF is decreased during aging, thereby reducing response to bevacizumab. Despite the decrease in VEGF, angiogenesis is increased because of an increase in sFRP2 in the aged tumor microenvironment. These results stress the importance of considering age as a factor for designing targeted therapies.